Full results from the study, presented at the American Heart Association annual scientific meeting in Philadelphia and published in the New England Journal of Medicine, suggest the drug has other beneficial effects beyond the known health benefits from losing weight.
The heart risk difference between patients who received Wegovy, known chemically as semaglutide, and those on placebo began to appear almost immediately after starting treatment, researchers said.
So it’s not just from losing weight!
The associated risk factors include inflammation, blood pressure and blood sugar control, all of which can impact heart health.
Patients on Wegovy experienced decreases in C-reactive proteins, an indication of inflammation, similar to those reported with cholesterol lowering statins, which are known to significantly lower heart risks, researchers reported.
That is really promising!
I like the choice of SIlverstone for the case. I got one of those for my proxmox server. It was compact, but not so compact that I left a lot of skin and blood behind after mounting components. I will say that other manufacturers (like Fractal Design just seem to understand how to design an interior a lot better, though.